OR WAIT null SECS
© 2021 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2021 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
December 03, 2021
December 02, 2021
December 01, 2021
A pair of experts in the management of diabetes review the role of insulin therapy and review the approval process for biosimilars, including the FDA's approval of the first interchangeable insulin biosimilar.
Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.
Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.
A study from Emory University details the risk of developing type 2 diabetes among transgender individuals compared to their cisgender counterparts and takes a deeper dive into the influence of gender-affirming hormone therapy on this risk
November 30, 2021
Results from a recent clinical trial indicate VX-880 stem cell-derived therapy demonstrated restoration of insulin production and was generally well-tolerated in T1D treatment.